Inactive Instrument

Analyst Reco. IPI Legacy Liquidation Co

Equities

IMPL

US45258K1097

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

North American Morning Briefing : Investors on -2-	Apr. 05	DJ
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	Nov. 20	DJ
Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike	23-09-08	MT
JonesTrading Downgrades Impel Pharmaceuticals to Hold From Buy	23-08-18	MT
Wedbush Adjusts Impel Pharmaceuticals' Price Target to $2 From $4, Maintains Neutral Rating	23-03-24	MT
Wedbush Trims Impel Pharmaceuticals' Price Target to $4 From $5 Following Announcement of Corporate Restructuring, Keeps Neutral Rating	23-02-23	MT
Wedbush Downgrades Impel Pharmaceuticals to Neutral From Outperform, Lowers Trudhesa Revenue Estimates as Commercial Traction Remains Elusive; Cuts PT to $5 From $24	22-11-15	MT
Cowen & Co Adjusts Impel Pharmaceuticals Price Target to $40 From $55, Maintains Outperform Rating	22-11-14	MT
Wedbush Cuts Price Target on Impel Pharmaceuticals to $24 From $28, Keeps Outperform Rating	22-10-13	MT
JonesTrading Starts Impel Pharmaceuticals at Buy With $26 Price Target	22-08-25	MT
Wedbush Lowers Price Target for Impel NeuroPharma to $28 From $31, Maintains Outperform Rating	22-08-15	MT
Wedbush Trims Impel NeuroPharma's Price Target to $31 From $32, Keeps Outperform Rating	22-04-28	MT
Guggenheim Adjusts Impel NeuroPharma Price Target to $35 From $50, Maintains Buy Rating	22-03-25	MT
Wedbush Lowers Impel NeuroPharma's Price Target to $32 From $40; Outperform Rating Kept	22-01-25	MT
Wedbush Lifts Price Target on Impel NeuroPharma to $40 From $39; Outperform Rating Kept	21-11-16	MT
IMPEL NEUROPHARMA : Wedbush Adjusts Impel NeuroPharma PT to $39 From $37, Maintains Outperform Rating	21-09-15	MT
ANALYST RECOMMENDATIONS : Adobe, Broadcom, Chipotle Mexican Grill, Netflix, Vodafone...	21-09-08
IMPEL NEUROPHARMA : Guggenheim Adjusts Impel NeuroPharma PT to $50 From $32, Maintains Buy Rating	21-09-07	MT
IMPEL NEUROPHARMA : Wedbush Adjusts Impel NeuroPharma PT to $37 From $31, Maintains Outperform Rating	21-09-07	MT
IMPEL NEUROPHARMA : Wedbush Adjusts Impel NeuroPharma PT to $31 From $25 Ahead of Investor Meeting on Trudhesa Launch Plans, Maintains Outperform Rating	21-09-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. IPI Legacy Liquidation Co

Equities

IMPL

US45258K1097

Analyst Reco.

Filters